To improve the shape and size of the vectors, the researchers merely transformation the attachment density of the peptides on the polymer scaffold, leading to shapes that change from spherical to donut formed to long filaments. These gene vectors can also be further conjugated with targeting molecules, which will allow us to provide the right genes to the proper spot in our body, Geng added. With the synthesis of the vector finish, the researchers now plan to evaluate how effective it is in integrating genes into tumor cells. Geng stated her ultimate goal is to use tumor-suppressor genes to take care of cancer. Another likelihood is by using the synthetic vectors to introduce genes that raise the disease fighting capability.The primary measure of efficacy was the hazard ratio for disease recurrence or death in the capecitabine group in comparison with the standard-chemotherapy group. Capecitabine will be considered noninferior to regular chemotherapy if the hazard ratio was higher than 0.8046. The planned sample size was 600 to 1800 patients. Interim monitoring for noninferiority and futility was planned following the enrollment of 600, 900, 1200, and 1500 individuals. Noninferiority and futility bounds were defined relating to Bayesian predictive probabilities with the use of noninformative prior distributions19 for the true treatment results.